Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
20.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Launches WorkBeads affimAb Edge: Strategic Expansion in the Protein A Resin Market | 1 | Cision News | ||
19.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works two largest shareholders have informed of their intention to exercise all their Warrants TO2 | 1 | Cision News | ||
14.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB will be publishing the Q2 interim report 2025 tomorrow Friday the 15'th of August | 2 | Cision News | ||
BIO-WORKS TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
15.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 3 of 11 | 1 | Cision News | ||
11.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives SEK 5.5 Million Order from Global Pharmaceutical Company | 1 | Cision News | ||
01.07. | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the third exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 2 | Cision News | ||
15.05. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives WorkBeads order worth SEK 2.5 million | 1 | Cision News | ||
15.05. | BIO-WORKS TECHNOLOGIES AB: Resolutions passed at Bio-Works Technologies' annual general meeting 2025 | 16 | Cision News | ||
15.05. | BIO-WORKS TECHNOLOGIES AB: Bio-Works reports first quarter 2025 | 1 | Cision News | ||
29.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order Worth SEK 2.4 Million from New European Customer in Vaccine Production | 1 | Cision News | ||
15.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 2 of 11 | 1 | Cision News | ||
14.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives SEK 12 million order from global pharmaceutical company - delivery scheduled for 2026 | 3 | Cision News | ||
01.04. | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the second exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 2 | Cision News | ||
27.03. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives New Orders for Custom GoBio Columns for the U.S. Gene Therapy Market | 2 | Cision News |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
JYONG BIOTECH | 52,22 | -2,28 % | Jyong Biotech Ltd.: Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS-8 for Prostate Cancer Prevention | New Taipei City, Taiwan, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company", "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen | |
QIAGEN | 38,905 | +1,16 % | QIAGEN N.V.: QIAGEN erhält europäische CE-IVDR-Zertifizierung für das gesamte QIAstat-Dx-Portfolio | Komplettes Portfolio an QIAstat-Dx-Panels ab jetzt CE-IVDR-zertifiziert und damit für den Einsatz in der klinischen syndromischen Testung zugelassen ein klares Bekenntnis zu Diagnostik auf höchstem... ► Artikel lesen | |
89BIO | 14,970 | +85,27 % | Milliarden-Pharma-Übernahme: Roche kauft sich in Biotech-Milliardenmarkt ein - 89bio im Fokus | © Foto: SOPA Images - Sipa USARoche kauft das US-amerikanische Biotech-Unternehmen 89bio für bis zu 3,5 Milliarden US-Dollar. Im Fokus steht ein Hoffnungsträger gegen die Fettleberkrankheit MASH, ein... ► Artikel lesen | |
BIONTECH | 81,80 | -1,51 % | Community-Rückblick: BNTX Rally nur von kurzer Dauer: "Die Top-Meldung ist zu nem Non-Event geworden" | BioNTech konnte einen Durchbruch nach der Phase-3-Studie zum Brustkrebspräparat "Trastuzumab Pamirtecan" vermelden. Diese Nachricht trieb die Aktie zweistellig nach oben. Die Rally war allerdings nur... ► Artikel lesen | |
EVOTEC | 6,292 | +1,26 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen | |
BEAM THERAPEUTICS | 25,120 | +11,79 % | Fortschritte in der Pipeline: H.C. Wainwright bestätigt "Buy"-Rating für Beam Therapeutics | ||
SUMMIT THERAPEUTICS | 19,280 | +6,58 % | Summit Therapeutics stock rating reiterated at Buy by H.C. Wainwright | ||
RAPPORT THERAPEUTICS | 27,350 | +3,91 % | Truist Securities initiates Rapport Therapeutics stock with Buy rating | ||
NURIX THERAPEUTICS | 8,970 | +4,67 % | Nurix reports promising preclinical data for IRAK4 degrader GS-6791 | ||
MINERALYS THERAPEUTICS | 39,880 | +6,95 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 4,925 | +4,34 % | What Analysts Are Saying About Recursion Pharmaceuticals Stock | ||
DAY ONE BIOPHARMACEUTICALS | 7,210 | +3,07 % | Day One Biopharmaceuticals, Inc.: Day One Reports First Quarter 2025 Financial Results and Corporate Progress | OJEMDA (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in... ► Artikel lesen | |
VIKING THERAPEUTICS | 22,140 | +13,35 % | AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play? | ||
PRIME MEDICINE | 5,120 | +10,23 % | Prime Medicine, Inc.: Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates | -- Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory interactions... ► Artikel lesen | |
TANGO THERAPEUTICS | 7,890 | +3,48 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights | - First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors - - First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5... ► Artikel lesen |